The biopharma flotation remains a rare beast
Few developers are feeling bold enough to brave the markets, though the bigger deals are finding some support.
Venture financing holds steady for device makers
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
Flotations tank in the first quarter
A correction – as long as it is not too severe – might not be a bad thing for the sector.
Medical device groups float – then sink
Medtechs rushed for the markets last year, but had an uneasy time once there.
After a record year, where next for biopharma flotations?
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
Biotech listings show signs of a slowdown
2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
EQRX aims for biopharma Spac record
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
Floating medtechs go big or go home
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
